Gilead Historical Cash Flow
| GILD Stock | USD 92.58 0.17 0.18% |
Analysis of Gilead Sciences cash flow over time is an excellent tool to project Gilead Sciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 3.5 B or Depreciation of 2.8 B as it is a great indicator of Gilead Sciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Gilead Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Gilead Sciences is a good buy for the upcoming year.
Gilead |
About Gilead Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Gilead balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Gilead's non-liquid assets can be easily converted into cash.
Gilead Sciences Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Gilead Sciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Gilead Sciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Gilead Sciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Depreciation is projected to increase significantly based on the last few years of reporting. The current year's Other Non Cash Items is expected to grow to about 2.3 B, whereas Change In Working Capital is projected to grow to (2.2 B).
Gilead Sciences cash flow statement Correlations
Click cells to compare fundamentals
Gilead Sciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Gilead Sciences cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (6.3B) | (5.6B) | (659M) | 74M | 673M | 706.7M | |
| Free Cash Flow | 8.3B | 7.5B | 10.8B | 8.3B | 7.4B | 4.2B | |
| Change In Working Capital | (798M) | (1.6B) | 489M | (1.8B) | (2.3B) | (2.2B) | |
| Begin Period Cash Flow | 17.9B | 11.6B | 6.0B | 5.3B | 5.4B | 3.5B | |
| Other Cashflows From Financing Activities | (122M) | 8.0B | (145M) | (173M) | (278M) | (264.1M) | |
| Depreciation | 1.4B | 1.5B | 2.1B | 2.1B | 2.7B | 2.8B | |
| Other Non Cash Items | 4.6B | 7.8B | 2.1B | 5.1B | 2.2B | 2.3B | |
| Capital Expenditures | 825M | 650M | 579M | 728M | 585M | 614.3M | |
| Total Cash From Operating Activities | 9.1B | 8.2B | 11.4B | 9.1B | 8.0B | 4.5B | |
| Net Income | 5.4B | 89M | 6.2B | 4.6B | 5.6B | 3.0B | |
| Total Cash From Financing Activities | (7.6B) | 770M | (8.9B) | (6.5B) | (5.1B) | (4.9B) | |
| End Period Cash Flow | 11.6B | 6.0B | 5.3B | 5.4B | 6.1B | 3.7B | |
| Change To Inventory | (310M) | (95M) | (195M) | 11M | (842M) | (799.9M) | |
| Change To Liabilities | (178M) | (58M) | 207M | (1.1B) | (1.3B) | (1.2B) | |
| Stock Based Compensation | 636M | 643M | 635M | 637M | 795M | 423.9M | |
| Total Cashflows From Investing Activities | (7.8B) | (14.6B) | (3.1B) | (2.5B) | (2.3B) | (2.4B) | |
| Change To Account Receivables | (218M) | (1.2B) | 313M | (406M) | 157M | 164.9M | |
| Other Cashflows From Investing Activities | (4.7B) | (25.9B) | (3.1B) | (1.8B) | (1.6B) | (1.7B) | |
| Change To Netincome | (478M) | 6.5B | 11.4B | 3.5B | 4.0B | 4.2B | |
| Sale Purchase Of Stock | (1.7B) | (1.6B) | (546M) | (1.4B) | (1B) | (1.1B) | |
| Investments | (2.3B) | 11.9B | (3.1B) | (2.5B) | (1.9B) | (1.8B) | |
| Change Receivables | (218M) | (1.2B) | 313M | (406M) | (466.9M) | (490.2M) | |
| Net Borrowings | (2.8B) | 5.7B | (4.8B) | (1.5B) | (1.4B) | (1.3B) | |
| Dividends Paid | 3.2B | 3.4B | 3.6B | 3.7B | (3.8B) | (3.6B) | |
| Cash And Cash Equivalents Changes | (6.3B) | (5.7B) | (624M) | 137M | 123.3M | 229.1M | |
| Cash Flows Other Operating | 3.3B | 1.5B | 689M | 727M | 836.1M | 664.3M | |
| Change To Operating Activities | (696M) | 426M | 647M | (705M) | (634.5M) | (602.8M) | |
| Issuance Of Capital Stock | 209M | 256M | 169M | 309M | 382M | 295.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.42) | Dividend Share 3.06 | Earnings Share 0.09 | Revenue Per Share 22.703 | Quarterly Revenue Growth 0.07 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.